Incyte Corp Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP, and what generic alternatives to INCYTE CORP drugs are available?
INCYTE CORP has three approved drugs.
There are twenty-four US patents protecting INCYTE CORP drugs.
There are three hundred and ninety-four patent family members on INCYTE CORP drugs in fifty countries and forty-one supplementary protection certificates in eighteen countries.
Summary for Incyte Corp
| International Patents: | 394 |
| US Patents: | 24 |
| Tradenames: | 3 |
| Ingredients: | 2 |
| NDAs: | 3 |
Drugs and US Patents for Incyte Corp
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 8,722,693*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-003 | Apr 17, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-003 | Nov 16, 2011 | RX | Yes | No | 8,822,481*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | 9,611,267 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for Incyte Corp Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| New Zealand | 603686 | ⤷ Try a Trial |
| Chile | 2014003355 | ⤷ Try a Trial |
| Japan | 6301321 | ⤷ Try a Trial |
| China | 103524509 | ⤷ Try a Trial |
| Denmark | 3495367 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Incyte Corp Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1966202 | CR 2013 00005 | Denmark | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823 |
| 2861595 | PA2021519,C2861595 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
| 2861595 | CA 2021 00033 | Denmark | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1535 20210329 |
| 2455382 | LUC00016 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/12/773/001-016 20150313 |
| 2861595 | 122021000054 | Germany | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
